In-vivo enzyme and preparation method and application thereof in inhibiting novel virus

An enzyme and virus technology, applied in the direction of bacteria, applications, and pharmaceutical formulations used in food preparation, can solve the problem of not suppressing the initial symptom mechanism of virus infection

Pending Publication Date: 2020-07-24
绵阳市润土农业科技开发有限公司
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] For this reason, the embodiment of the present invention provides an in vivo enzyme and its preparation method and its application in inhibiting new viruses, so as to solve the p...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • In-vivo enzyme and preparation method and application thereof in inhibiting novel virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0080] This example provides an in vivo enzyme, including 5 parts of astragalus polysaccharides, 60 parts of inulin, 8 parts of xylooligosaccharides, 20 parts of isomaltooligosaccharides, 1.5 parts of dietary fiber, 5 parts of compound fruit and vegetable extracts, and Lactobacillus acidophilus , Thermophilic Lactobacillus, Bifidobacterium longum, Lactobacillus plantarum 0.1 part each, Saccharomyces cerevisiae 0.2 part, papain 0.2 part, vitamin C 0.2 part, salt 0.1 part.

[0081] The preparation method of the enzyme in vivo is as follows: dry mix astragalus polysaccharides, inulin, xylo-oligosaccharides, isomalto-oligosaccharides, compound fruit and vegetable extracts, and salt, then sterilize at high temperature, and then passivate and dormant the active strains , after three times of embedding, mix it with Saccharomyces cerevisiae, papain, and vitamin C in a three-dimensional mixer for 1 hour, until it is fully mixed and wrapped completely, and then packaged to obtain the fin...

Embodiment 2

[0083] The present embodiment provides an enzyme in vivo, including 5 parts of yam polysaccharide, 60 parts of inulin, 3 parts of konjac mannan, 5 parts of isomaltooligosaccharide, 1.5 parts of dietary fiber, 5 parts of compound fruit and vegetable extract, Steviol glycoside, Streptococcus thermophilus, Lactobacillus reuteri, Bifidobacterium adolescentis, Lactobacillus crispatus each 0.1 part, Saccharomyces cerevisiae: 0.2 part, bromelain: 0.2 part, vitamin C: 0.2 part, salt: 0.1 part.

[0084] The preparation method of the enzyme in vivo is as follows: dry mix yam polysaccharide, inulin, konjac mannan, isomaltooligosaccharide, compound fruit and vegetable extract, steviol glycoside, and salt, and then sterilize at high temperature, and then passivate the dormant The active strain of the active strain is mixed with Saccharomyces cerevisiae and bromelain in a three-dimensional mixer for 1 hour after three times of embedding, until it is fully mixed and wrapped completely, and th...

Embodiment 3

[0086]This example provides an in vivo enzyme, including 2 parts of ginseng polysaccharide, 60 parts of inulin, 3 parts of polydextrose, 5 parts of galacto-oligosaccharide, 1.5 parts of dietary fiber, 5 parts of compound fruit and vegetable extract, and Lactobacillus sugar, Lactobacillus helveticus, Bifidobacterium breve, Bifidobacterium lactis, Propionibacterium freunderi subspecies Shermania each 0.1 parts, Saccharomyces cerevisiae: 0.2 parts, ficin: 0.2 parts, vitamin E microcapsules: 0.2 parts , Salt: 0.1 parts.

[0087] The preparation method of the enzyme in vivo is as follows: ginseng polysaccharides, inulin, polydextrose, galactooligosaccharides, compound fruit and vegetable extracts, and salt are dry mixed and then sterilized at high temperature, and then the active strains that have been passivated and dormant are subjected to After three times of embedding, mix with Saccharomyces cerevisiae, ficin, and vitamin E microcapsules in a three-dimensional mixer for 1 hour ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an in-vivo enzyme and a preparation method and an application thereof in inhibiting novel virus. The preparation method comprises the steps that beneficial microorganisms are added into a raw material, wherein the beneficial microorganisms establish a microflora intention confrontation mechanism in vivo, the microorganisms and intestinal flora are cooperatively fermented togenerate endogenous interferon. The endogenous interferon blocks a virus replication system and enhances immunity to inhibit various pathogenic microorganisms, wherein the pathogenic microorganisms comprise prion, spirochete, mycoplasma, rickettsia, and variants of novel virus. According to the in-vivo enzyme provided by the invention, by establishing a microbial countermeasure model, an in-vivomicrobial dominant population is artificially established in the microscopic world, and invasion of other pathogenic microorganisms is selectively inhibited. Counterfeiting in the microscopic world can accelerate the immune system in the human body to generate the antibody of the virus, so that various viruses coexist in the microscopic world, and the synergistic effect of various beneficial microorganisms can relieve the influence of cytokine storm on organs.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to an in vivo enzyme, its preparation method and its application in inhibiting novel viruses. Background technique [0002] Since the birth of life on the earth, viruses have always existed, and are constantly mutating and evolving. The virus itself is not a complete cell, so all current drugs cannot directly kill the virus, but design different drugs through different links from the adsorption, penetration and uncapsiding of virus-infected cells, viral nucleic acid replication, assembly and release, etc. Prevent virus replication. In the past 50 years, the drug research for the treatment of bacterial infections has made great progress, while the research progress of antiviral drugs lags behind obviously. So far, humans have not found an effective way to kill viruses, or invented specific antiviral drugs. Most of them use vaccines or the body's own immunity to work. [0003] After be...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A23L33/125A23L33/21A23L33/105A23L33/135A23L33/10A23L33/15A23L27/40A61K35/745A61K35/747A61P37/04A61P31/04
CPCA23L33/125A23L33/21A23L33/105A23L33/135A23L33/10A23L33/15A23L27/40A61K35/745A61K35/747A61P37/04A61P31/04A23V2002/00A61K2300/00A23V2400/133A23V2400/175A23V2400/147A23V2400/519A23V2400/531A23V2400/517A23V2200/30A23V2200/324A23V2200/3202A23V2250/21A23V2250/51A23V2250/28A23V2250/708A23V2250/762A23V2400/113A23V2400/533A23V2400/169A23V2400/249A23V2400/173A23V2400/513Y02A50/30
Inventor 张永
Owner 绵阳市润土农业科技开发有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap